

Communiqué from the extraordinary general meeting of Swedencare AB (publ)

The extraordinary general meeting (EGM) of Swedencare AB (publ) took place on Wednesday, 19 October 2022. The extraordinary general meeting was conducted by postal voting, without physical attendance. Complete information and documentation regarding the EGM's decision can be found on the company's website, www.swedencare.com. The EGM resolved in line with all of the motions presented in the notification of the EGM.

Resolution regarding incentive program, comprising a private placement and assignment of warrants

The EGM resolved, in accordance with the Board's proposal, on an incentive program for employees in the Swedencare Group, comprising a private placement of not more than 415,000 warrants to the company and assignment of warrants to the participants in the incentive program. The transfer of the warrants to the participants in the incentive program shall take place at market value.

Each warrant entitles the holder, during the period from 1 December 2025 to 28 February 2026, to subscribe for one (1) new share in Swedencare at a subscription price amounting to 135 percent of the volume-weighted average price paid for the company's share on Nasdaq First North Growth Market during the period from 12 October 2022 to 18 October 2022. The company's share capital can increase by a maximum of SEK 4,150 which corresponds to a dilution effect of at most about 0.26 percent.

For more information, please contact:

Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se

FNCA is the Certified Adviser of the Company

Please visit the Company homepage www.swedencare.com

About Swedencare

Swedencare, a listed company on NASDAQ First North Growth Market, specializes in pet healthcare and produces, markets and sells premium products in the global and fast-growing market. The company has a wide range of strong brands and products within most therapy areas, including Animal Pharmaceuticals®, Nutravet®, NutriScience, Pet MD®, Stratford®, VetWELL®, NaturVet® as well as ProDen PlaqueOff® for oral health to dogs and cats. Swedencare's headquarter is in Malmö, Sweden with subsidiaries located in nine countries with products sold in more than sixty countries. Swedencare's sales have increased significantly over the last few years with strong margins and profits.

Attachments

[Communiqué from the extraordinary general meeting of Swedencare AB \(publ\)](#)